New Scientist Colab Podcasts

Show Notes

💬 Artificial intelligence and big data are flooding discovery pipelines with high-potential drug candidates, but this rapid innovation has triggered significant challenges. Simply put, our capability to design miracle molecules is vastly outstripping our technology to mass-manufacture them safely for the global public. Moving drug making from the scale of lab flasks to commercial bioreactors introduces non-linear biological and engineering shifts that can undermine tasks like purification.

⚡In this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science of purification that is required to close the gap between drug discovery and the pharmacy shelf.

Our guests are:

Henrik Ihre, Distinguished Fellow, Cytiva

Paul Belcher, Business Leader, Cytiva



🎧 Stay tuned to learn about:

➡ The process of taking a drug from theoretical to the shop shelf

➡ How the drug purification works

➡ The human cost when purification goes wrong

➡ The challenges of keeping pace in manufacturing as AI supercharges drug discovery



Chapters:

(00:00) Intro - How drugs go from discovery to reality

(03:49) The purification process

(10:05) Why small scale success doesn't mean industrial scale success

(13:00) The challenge of the expanding drug pipeline

(21:39) Understanding the molecules that are being purified

(23:20) What is a chromatography resin?

(25:24) Why purification gets more difficult later in the process

(27:15) The human impact when purification goes wrong

(32:59) The future of AI drug discovery

(37:52) Is AI helping with purification?

(40:32) How it feels to be advancing drug discovery



About the sponsor:

Cytiva: ⁠https://www.cytivalifesciences.com/ ⁠



About the podcast:

New Scientist CoLab explores the boundaries of innovation and the intersection of business, science and technology. Hosted by Justin Mullins.

Don't miss an episode - subscribe now:

⁠https://www.youtube.com/@NewScientistCoLab⁠




Connect with New Scientist:

Website: ⁠https://www.newscientist.com/⁠

Instagram: ⁠https://www.instagram.com/newscientist/⁠

Learn more about your ad choices. Visit megaphone.fm/adchoices

💬 The longevity space isn’t just for humans. Science is uncovering new ways to keep our pets healthier for longer too. New research is finally uncovering why our dogs and cats slow down with age - and how we can slow that process.

⚡ So what lifestyle changes can help our pets live longer, healthier lives? In this episode, sponsored by Royal Canin, we explore emerging research exploring the hallmarks of ageing, with practical tips for all pet owners.

Our guests are:

Dr Tanya Schoeman, veterinary specialist physician with Royal Canin

Dr Cat Henstridge, veterinary surgeon and online educator (@cat_the_vet)

Don't miss an episode - subscribe now:

https://www.youtube.com/@NewScientistCoLab 

🎧 Stay tuned to learn about:

➡ The importance of the human-animal bond in pet longevity

➡ How to stave off chronic inflammation in our pets

➡ Why nutrition and dental health are the fundamentals of keeping our pets healthy

➡ The barriers vets have to overcome when caring for our pets

➡ Why prevention is always better than cure.

Chapters:

(00:00) Intro - Pet ageing is not inevitable

(02:53) Difference between  chronological age and biological age

(05:00) Importance of the human-animal bond

(11:41) How inflammation impacts the health of our pets

(15:30) Understanding the hallmarks of ageing

(20:34) Impact of the COVID pet boom

(26:01) Barriers to care

(29:22) Can you accurately measure your pet’s biological age?

(33:52) The burden of pet ageing on owners

(38:42) Top tips for all pet owners

About the sponsor:

Royal Canin

About the podcast:

New Scientist CoLab explores the boundaries of innovation and the intersection of business, science and technology. Hosted by Justin Mullins.

Connect with New Scientist:

Website: https://www.newscientist.com/ 

Instagram: https://www.instagram.com/newscientist/ 

Learn more about your ad choices. Visit megaphone.fm/adchoices

💬 Over the last decade, advances in subsurface imaging have meant we’re able to see deep within our planet with unfathomable detail - pinpointing vast geological structures beneath our oceans with unprecedented accuracy.

⚡ Viridien is the company creating these incredible images and in this episode they explore the breakthroughs that are revolutionising subsurface imaging and helping to see the geological details of the Earth in ever higher definition.

Our guests are:

Gordon Poole, UK research manager at Viridien

Ewa Kaszycka UK, Geoscience Manager at Viridien.

Don't miss an episode - subscribe now:

https://www.youtube.com/@NewScientistCoLab 

🎧 Stay tuned to learn about:

➡ How full waveform inversion (FWI) peels back the data to reveal amazing images

➡ Why high performance computing (HPC) is integral in processing seismic data

➡ How boats can spend 3 months gathering data without breaks

➡ How subsurface images help capture carbon - reducing the impacts of climate change

➡ What it takes to work at a company like Viridien

Chapters:

(00:00) Intro

(01:05) Early work in geophysics

(02:37) The revolutions that have transformed subsurface imaging

(04:27) How data is converted into images with full waveform inversion

(07:19) How Albert Tarantola’s vision became reality

(09:32) The many different skills needed for this work

(10:27) The important role of high performance computing

(12:28) The data gathered by ocean bottom nodes

(14:57) How Viridien makes its approach sustainable

(17:19) What’s coming in the future?

(19:17) How subsurface images allow great carbon storage

(22:54) What else is becoming possible thanks to better subsurface images?

(27:49) The biggest unsolved problems in the field

(30:10) The defining properties of people who work in this sector

About the sponsor:

Viridien is a multinational geoscience and technology company that is pushing the  boundaries of Earth subsurface imaging.

About the podcast:

New Scientist CoLab explores the boundaries of innovation and the intersection of business, science and technology. Hosted by Justin Mullins.

Connect with New Scientist:

Website: https://www.newscientist.com/ 

Instagram: https://www.instagram.com/newscientist/ 

Learn more about your ad choices. Visit megaphone.fm/adchoices

About this episode

SXSW London is the preeminent forum for the new ideas and
leading thinkers who are sculpting the future. In this episode, we talk to Kat Sherling, head of conference at the event to explore the cultural and
technological forces driving the agenda at this year’s festival and discover
some of the speakers who will be there in June.

This is a New Scientist CoLab production, sponsored by the SXSW
London.

Your host is Justin Mullins.

Find out more about how we’re adapting to a rewired world with this New Scientist CoLab article : https://www.newscientist.com/article/2517346-can-humanity-find-a-place-in-the-rewired-world/
Learn more about your ad choices. Visit megaphone.fm/adchoices

The production of medicines is a high-stakes industry where efficiency and environmental impact often collide.  Given that the pharmaceutical industry is one of society’s biggest polluters, solving this challenge requires massive, cross-continent collaboration to spark real change.

In this episode, we explore how some of the UK and Europe’s premier research institutes and pharmaceutical companies have joined forces to pioneer "greener" production methods. This work is funded by Horizon Europe, the European Union’s flagship €96 billion research and innovation funding programme.

We visit Barcelona to talk to Dr Laura Rodriguez and Dr Andrés Cruz from IRIS Technology Solutions. They share how their collaboration with UK research teams has yielded impressive results—and why the partnership itself has been a key factor in the success.

This is a New Scientist CoLab production, sponsored by the UK Government.

For more information and to find a UK partner for your next Horizon Europe bid, click here.

Your host is James Randerson.

Read more about the UK-Spanish partnerships solving pharma’s
toughest challenges.

Learn more about your ad choices. Visit megaphone.fm/adchoices